Tempest Therapeutics announces publication highlighting TPST-1495

Tempest Therapeutics announced that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research. “While the biology of PGE2 in promoting tumor growth and immune suppression is well established, there are still no approved drugs for cancer that effectively block the prostaglandin pathway,” said Tom Dubensky, Ph.D., president of Tempest. “Our innovation with TPST-1495 shows for the first time the effect of blocking PGE2 signaling through the EP2 and EP4 pro-tumor receptors while maintaining the important anti-tumor signaling of PGE2 through the EP1 and EP3 receptors, which could be an important advance to inhibiting PGE2. Additionally, these results further support what we believe is an innovative and robust pipeline at Tempest that includes TPST-1120, a novel PPAR antagonist, which has shown early positive data from an ongoing global randomized study in first-line HCC patients.”